IP Library Granted Patent US 7,790,393
Granted Patent B2
US 7,790,393 · App. 12/174,277 · Granted Sep 7, 2010

Amplification methods and compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,393
App. No.
12/174,277
Granted
Sep 7, 2010
Kind
B2
Abstract

The present invention provides methods and routines for developing and optimizing nucleic acid detection assays for use in basic research, clinical research, and for the development of clinical detection assays. In particular, the present invention provides methods for designing oligonucleotide primers to be used in multiplex amplification reactions. The present invention also provides methods to optimize multiplex amplification reactions.

Claims (19)

1. A method of multiplex amplification of nucleic acid target regions, comprising:

a) providing a sample containing genomic DNA, wherein said genomic DNA comprises a plurality nucleic acid target regions, wherein each nucleic acid target region comprises a footprint region that is at least twenty bases in length and is suspected of containing a SNP;

b) amplifying said plurality of nucleic acid target regions from said genomic DNA to produce a first set of amplified products comprising amplified nucleic acid target regions, wherein said amplifying is in a first polymerase chain reaction mixture comprising a plurality of primer pairs, wherein each primer in said plurality of primer pairs in said first polymerase chain reaction mixture is present at essentially the same initial molar concentration, and wherein said primer pairs are each configured to amplify a nucleic acid target region;

c) determining an amplification factor F for each amplified nucleic acid target region in said first set of amplified products, wherein said amplification factor F is the ratio of amplified nucleic acid target region concentration after amplification to initial nucleic acid target region concentration,

d) determining an apparent initial primer concentration from said determined amplification factor F for each nucleic acid target region, wherein:

F =(2− e −k a ct ) n

wherein k a is the association rate constant of primer annealing, c is the initial primer concentration, t is the primer annealing time and n is the number of PCR cycles,

e) determining a relative primer concentration value R[n] for each given nucleic acid target region, wherein R[n] is equal to the highest observed apparent primer concentration of all amplified nucleic acid target regions in said first set of amplified products, divided by the apparent primer concentration for the given amplified nucleic acid target region;

f) determining a normalized primer concentration, wherein the normalized primer concentration for each given nucleic target region, is the value of R[n] for the corresponding amplified nucleic acid target region of step e) multiplied by the initial molar concentration of primers used in step b);

g) amplifying said plurality of nucleic acid target regions from said genomic DNA to produce a second set of amplified products, wherein said amplifying is in a second polymerase chain reaction mixture comprising a plurality of primer pairs, wherein said primers in said plurality of primer pairs in said second polymerase chain reaction mixture are present in said normalized primer concentrations so as to balance the amplification factors for said amplified nucleic acid target regions in said second set of amplified products.

2. The method of claim 1 , further comprising step h) of detecting said second set of amplified products.

3. The method of claim 1 , wherein said determining an amplification factor F for each amplified nucleic acid target region comprises exposing said first set of amplified products to invasive cleavage assay reagents.

4. The method of claim 1 , wherein said detecting comprises exposing said second set of amplified products to invasive cleavage assay reagents.

5. The method of claim 1 , wherein said plurality of primer pairs in step b) comprises at least 150 primer pairs.

6. The method of claim 3 , wherein said invasive cleavage assay reagents comprise a plurality of an upstream oligonucleotides and a downstream probe oligonucleotides configured to hybridize to said footprint regions to form invasive cleavage structures.

7. The method of claim 6 , wherein said invasive cleavage assays reagents comprise 150 or more probe oligonucleotides.

8. The method of claim 6 , wherein said invasive cleavage assay reagents further comprise a cleavage agent.

9. The method of claim 3 , wherein the presence or absence of SNPs in said footprint regions is detected by said invasive cleavage assay reagents.

10. The method of claim 1 , wherein said detecting comprises detection of fluorescence.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
MERGER Recorded Oct 23, 2015
From: THIRD WAVE AGBIO, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: GEN-PROBE INCORPORATED
Reel/Frame 036934/0796 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2008
From: LYAMICHEV, VICTOR; LUKOWIAK, ANDREW; JARVIS, NANCY; KURENSKY, DAVID
To: THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 021295/0490 →